Madrigal Pharmaceuticals, Inc. | TalkMarkets | Page 1
No data available
No data available

People who follow this stock (19)

View All

Latest Posts

About This Stock More About This Stock
2 Top Biotech Buyout Candidates
Article By: Andrew Rocco
Sunday, March 31, 2024 4:00 PM EDT
Investors who are adventurous, have a high-risk tolerance, and are home run hitters may opt for biotech stocks. Investors in this group may want to hone in on stocks that have the potential to be bought out. Here are some top buyout candidates.
In this article: VKTX, MDGL Also: LLY, NVO, IBB, XBI
Read
Madrigal Pharmaceuticals: A "Best In Class" Biotech Buy
Article By: MoneyShow.com
Thursday, February 17, 2022 10:23 AM EDT
One of the few broadly positive binary events in biotechnology of late, Madrigal’s best-in-class NASH compound is well on its way with de-risked, late-stage clinical results.
In this article: MDGL
Read
Top Picks For 2022: Madrigal Pharmaceuticals
Article By: MoneyShow.com
Saturday, January 22, 2022 4:15 PM EDT
Madrigal Pharmaceuticals is poised to deliver positive Phase III data in 2022 for resmetirom, its best-in-class NASH (nonalcoholic steatohepatitis) compound.
In this article: MDGL
Read
Madrigal Pharmaceuticals Announces Pricing Of Secondary Offering
Article By: NASDAQ GlobeNewswire
Tuesday, December 10, 2019 10:18 PM EDT
Madrigal Pharmaceuticals, Inc. today announced the pricing of the previously-announced underwritten secondary offering by investment funds affiliated with Bay City Capital LLC, of 1,200,000 shares of Madrigal’s common stock.
In this article: MDGL
Read
Why Madrigal Pharma Boasts 133% Upside
Article By: TipRanks
Monday, November 19, 2018 8:23 AM EDT
Earlier this month, Madrigal announced its Q3 earnings results, and the effect of the earlier stock offerings was clear. The company reported operating expenses of $11.3 million, R&D expenses of $6.2 million, and a $19.2 million cash burn.
In this article: MDGL
Read
All Posts

Latest Tweets for $MDGL

No tweets yet!

PARTNER HEADLINES